NCT00131469View on ClinicalTrials.gov

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

Teriparatide (FORTEO)

Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily

DRUG

Placebos

Trial Locations (3)

21205

Kennedy Krieger Institute, Baltimore

77030

Baylor College of Medicine, Department of Molecular and Human Gentics, Houston

97239-3098

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Osteogenesis Imperfecta Foundation

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Oregon Health and Science University

OTHER

NCT00131469 - Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta | Biotech Hunter | Biotech Hunter